(Q40564857)

21 September 2017

title

The cholera toxin B subunit directly costimulates antigen-primed CD4+ T cells ex vivo (English)

1 reference

21 September 2017

0 references

M Wang

1

1 reference

21 September 2017

S Bregenholt

series ordinal

2

1 reference

21 September 2017

J S Petersen

series ordinal

3

1 reference

21 September 2017

publication date

1 September 2003

1 reference

Scandinavian Journal of Immunology

21 September 2017

published in

1 reference

21 September 2017

volume

58

1 reference

21 September 2017

issue

3

1 reference

21 September 2017

page(s)

342-349

1 reference

Cholera toxin and cholera B subunit as oral-mucosal adjuvant and antigen vector systems

21 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-3083.2003.01308.X

Treatment of experimental autoimmune encephalomyelitis by feeding myelin basic protein conjugated to cholera toxin B subunit

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-3083.2003.01308.X

A cholera toxoid-insulin conjugate as an oral vaccine against spontaneous autoimmune diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-3083.2003.01308.X

Induction of mucosal and systemic immune responses by intranasal immunization using recombinant cholera toxin B subunit as an adjuvant.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-3083.2003.01308.X

Recombinant cholera toxin B subunit acts as an adjuvant for the mucosal and systemic responses of mice to mucosally co-administered bovine serum albumin

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-3083.2003.01308.X

Mucosal immunization against hepatitis B virus by intranasal co-administration of recombinant hepatitis B surface antigen and recombinant cholera toxin B subunit as an adjuvant

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-3083.2003.01308.X

The cholera toxin B subunit is a mucosal adjuvant for oral tolerance induction in type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-3083.2003.01308.X

Immunomodulation using bacterial enterotoxins

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-3083.2003.01308.X

Genetically manipulated bacterial toxin as a new generation mucosal adjuvant

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-3083.2003.01308.X

Oral administration of recombinant cholera toxin subunit B inhibits IL-12-mediated murine experimental (trinitrobenzene sulfonic acid) colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-3083.2003.01308.X

Cholera toxin B pretreatment of macrophages and monocytes diminishes their proinflammatory responsiveness to lipopolysaccharide

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-3083.2003.01308.X

Cholera toxin B subunit as a carrier molecule promotes antigen presentation and increases CD40 and CD86 expression on antigen-presenting cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-3083.2003.01308.X

Induction of tolerance in macrophages by cholera toxin B chain

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-3083.2003.01308.X

Prolonged oral treatment with low doses of allergen conjugated to cholera toxin B subunit suppresses immunoglobulin E antibody responses in sensitized mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-3083.2003.01308.X

Differential induction of programmed cell death in CD8+ and CD4+ T cells by the B subunit of cholera toxin

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-3083.2003.01308.X

10.1046/J.1365-3083.2003.01308.X

21 January 2018

Identifiers

DOI

1 reference

21 September 2017

1 reference